Travel Vaccines Market Size & Share 2025 - 2034

Travel Vaccines Market Size

The global travel vaccines market was estimated at USD 4.9 billion in 2024. The market is expected to grow from USD 5.2 billion in 2025 to USD 12.1 billion in 2034, growing at a CAGR of 9.9%. The market is poised for significant growth, driven by combination of global health trends, technological advancements and shifting travel patterns.

The growing awareness for region-specific infectious diseases and the importance of preventive measures is driving higher demand for immunization prior to travel. This heightened awareness is further reinforced by digital health platforms, government healthcare initiatives, and educational campaigns, positioning travel vaccines as a fundamental aspect of pre-travel planning and boosting market demand.
 

Travel vaccines are preventive immunization designed to protect individuals from infectious disease such as Hepatitis, yellow fever, typhoid, rabies, and other regions specific diseases. Major players in the industry include GlaxoSmithKline plc (GSK), Sanofi, Pfizer, and Merck, among others. These companies are leveraging innovation in vaccine technology, and global reach responding to emerging infectious threats.
 

The market substantially increased from USD 3.7 billion in 2021 to USD 4.4 billion in 2023. While growth during the pandemic was subdued due to widespread lockdowns and travel restrictions that limited exposure to infectious agents, the post-pandemic resurgence in outbound travel has reignited demand for travel-related immunization. The reopening of international borders and the rebound of tourism and business travel have led more travelers to proactively prioritize health precautions, especially for regions with endemic diseases.
 

According to the United Nations World Tourism Organization (UNWTO), Italy saw a sharp rise in tourist arrivals, from 38.42 million in 2020 and 40.19 million in 2021 to 74.32 million in 2022. This rebound in international travel is expected to accelerate the demand for travel-specific vaccines, reversing the earlier decline and supporting a steady market recovery
 

Advancements in vaccines development, such as single-dose formulations, mRNA technology, scalable manufacturing processes and improved cold-chain logistics, are streamlining production and distribution, enhancing global accessibility. These innovations are particularly impactful in developing regions, where improved vaccine access can significantly broaden market reach.
 

The travel vaccine market is categorized into mono vaccine and combination vaccines, distributed through public and private channels. These vaccines are essential in mitigating health risks associated with both international and domestic travel, especially to destinations with poor sanitation or high disease prevalence.
 

Travel Vaccines Market Trends

• With global travel on the rise, travelers are increasingly adapting their behaviors to prioritize safety and preventive care. According to the UNWTO, global international tourist arrivals are expected to exceed 1.4 billion in 2024, an increase of 11% over 2023, presenting a large addressable market for travel-related vaccines.
   
• Increasingly, travelers are recognizing the risks associated with region-specific diseases such as yellow fever, Japanese encephalitis, typhoid, rabies and meningococcal meningitis. As a result, travel vaccines are becoming standard practice for those embarking on international leisure, business, volunteer, or adventure travel.
   
• Platforms such as TravelHealthPro, CDC Traveler's Health, and private apps like Practo, Zocdoc, and MyVaccinationHub are simplifying vaccine recommendations and bookings. These tools enhance access to information, boost vaccine compliance, and enable personalized vaccine schedules based on destination, duration, and traveler profile.
   
• Vaccine makers are increasingly focusing on rapid-acting, single-dose, combination, and thermostable formulations, ideal for last-minute travelers and tropical conditions. For instance, innovations in typhoid conjugate vaccines (TCVs) and mRNA-based platforms may allow faster protection with fewer side effects, improving uptake among hesitant populations.
   
• Collaboration between governments, global health bodies and vaccine manufacturers is improving vaccine coverage in rural and high-risk regions.
   
• Further, multinational companies are instituting corporate travel health policies that require employees traveling to high-risk regions to be vaccinated as part of risk mitigation. This corporate-driven demand is fueling B2B opportunities for vaccine providers and occupational health partners.
   

Travel Vaccines Market Analysis

The global market was valued at USD 3.7 billion in 2021. The market size reached USD 4.4 billion in 2023, from USD 4.1 billion in 2022.
 

Based on the vaccine type, the market is segmented into mono vaccines and combination vaccines. The mono vaccines segment accounted for the largest revenue of USD 2.9 billion in 2024 due to their targeted protection against specific diseases that are commonly prevalent in travel destinations. The segment is expected to exceed USD 7.1 billion by 2034, growing at a CAGR of 9.7% during the forecast period.
 

• Mono vaccines such as those for Hepatitis A, typhoid, yellow fever, and rabies are among the most frequently recommended immunizations for international travelers, particularly those visiting developing regions with suboptimal hygiene and sanitation standards.
   
• Another key advantage of mono vaccines is their precision targeting, which provides immunity against a single pathogen, resulting in fewer adverse reactions and better tolerability compared to combination vaccines. This makes them a preferred option among healthcare providers, especially for travelers with specific medical conditions, allergies, or immunocompromised states.
   
• Additionally, regulatory bodies in several countries are mandating certain mono vaccinations guidelines prior to arriving in the disease-prone regions, further boosting their uptake.
   
• Public health campaigns, often supported by travel clinics, embassies, and digital health portals, are creating greater awareness among outbound travelers regarding the importance of targeted disease prevention.
   

Based on the disease type, the travel vaccines market is segmented into hepatitis A, meningococcal diseases, influenza, diphtheria, pertussis, tetanus (DPT), rabies, yellow fever, typhoid, measles, mumps, and rubella (MMR), Hepatitis B, and other disease types. The Hepatitis A vaccine segment accounted for the largest market share of 20.2% in 2024, reflecting its critical role in preventing one of the most common vaccine-preventable travel-related infections. The high incidence of Hepatitis A in popular travel destinations, particularly across Asia, Africa, and Latin America, continues to drive robust demand among outbound and domestic travelers.
 

• Hepatitis A is primarily transmitted through the ingestion of contaminated food and water, making it a significant threat in areas with limited sanitation infrastructure. Travelers consuming street food, visiting rural regions, or staying in local accommodations are particularly vulnerable, even on short-duration trips.
   
• Due to the widespread nature of this risk, global health agencies, including the CDC, WHO, and ECDC, strongly recommend Hepatitis A vaccination for most international travelers. Many travel clinics and national travel advisories include it as a core component of pre-travel vaccination schedules.
   
• The high efficacy rate combined with the potential for long-lasting or lifelong immunity, positions the Hepatitis A vaccine as a cornerstone of preventive care. This durability not only benefits individual travelers but also reduces the risk of disease importation and outbreaks upon return.
   
• Additionally, the availability of both standalone and combination Hepatitis A vaccines further enhances its accessibility and adoption, solidifying its leadership in the market.
   

Based on application, the travel vaccines market is segmented into outbound travel and domestic travel. The outbound travel segment accounted for the highest market share in 2024 and is expected to reach USD 7.9 billion by 2034, driven by heightened exposure to infectious diseases in international destinations, particularly in developing regions with lower public health infrastructure.
 

• Travelers heading to countries in Asia, Latin America, and Africa face elevated risks of contracting diseases such as Hepatitis A, Japanese encephalitis, yellow fever, typhoid, and rabies, due to endemic presence and limited sanitation or vector control. As a result, pre-travel immunization is routinely advised by healthcare authorities and mandated in many cases.
   
• The growth of global tourism, along with rising business travel, academic exchange programs and medical tourism, has significantly expanded the outbound traveler base. With more people crossing borders for diverse purposes, the need for travel-related preventive healthcare has surged.
   
• Increasing awareness of region-specific health risks coupled with greater access to travel health information via digital platforms and government advisories, has encouraged travelers to proactively seek vaccinations before departure. This shift in traveler behavior further reinforces demand in the outbound segment.
   
• In addition, vaccine manufacturers are responding to outbound travel trends by developing combination vaccines and fast-acting formulations, catering to time-constrained travelers who need protection against multiple diseases in a single visit.
   

Based on the age group, the travel vaccines market is segmented into pediatric and adult. The adult segment accounted for the highest market share of 73.4% in 2024, primarily due to the high volume of adult travelers undertaking both leisure and business trips across domestic and international destinations. This demographic is expected to continue driving the majority of vaccine demand through the forecast period.
 

• Adults are the primary demographic engaging in domestic and outbound travel and are likely to encounter infectious diseases such as Hepatitis A, typhoid, yellow fever, and rabies, thereby making them a key target for travel immunization.
   
• This age group is also more likely to seek pre-travel medical advice, schedule vaccinations in advance, and comply with official health recommendations. Factors such as corporate travel policies, immigration health requirements, and heightened health awareness, especially in the post-pandemic era, encourage responsible travel behavior among adults.
   
• Travel clinics, private healthcare providers, and pharmacies often tailor their services and marketing efforts specifically toward adult travelers.
   
• Vaccine programs are designed with the adult population in mind, offering flexible options like single-dose regimens, express vaccination services, and digital vaccination certificates that suit tight travel schedules.
   

Based on the end use, the travel vaccines market is segmented into online channel and offline channel. The hospital segment dominated the market in 2024, generating the highest revenue of USD 2.4 billion, driven by the widespread availability of comprehensive immunization services and access to experienced medical professionals.
 

• The segment is further divided into public and private hospitals, both playing critical roles in delivering pre-travel vaccination services across urban and semi-urban regions. Hospitals are often the primary point of contact for individuals planning international or high-risk travel, offering end-to-end health consultations that include risk assessments, vaccination planning, and certification.
   
• Hospitals provide an extensive portfolio of travel-related vaccines, including Hepatitis A, typhoid, yellow fever, rabies, meningococcal meningitis, and MMR (measles, mumps, rubella), making them a one-stop destination for outbound travelers seeking complete preventive coverage.
   
• One of the key advantages is the availability of cold-chain management infrastructure and qualified staff, which ensures the safe storage, handling, and administration of temperature-sensitive vaccines. This is especially critical for vaccines, which require stringent temperature control.
   
• In addition, hospital-based vaccination programs often follow standardized clinical protocols and documentation practices, instilling greater trust and reliability among patients, particularly among business travelers, older adults, and families traveling with children.
   

North America dominated the global travel vaccines market with the highest market share of 43.9% in 2024.
 

In 2024, U.S. market accounted for USD 1.9 billion revenue from USD 1.8 billion in 2023 and is anticipated to grow at a CAGR of 9.3% between the 2025 to 2034 period.
 

• This growth is driven by high outbound travel rates, exemplified by over 10 million international departures in December 2024 alone (up 7.7% YoY per the International Trade Administration).
   
• Federal support from agencies like the CDC has fueled adoption through public health campaigns and immunization guidelines.
   
• The presence of leading players such as Pfizer, Merck, and Sanofi, combined with widespread insurance coverage and digital health platforms, supports U.S. market dominance.
   
• Further, the Canada travel vaccine market is expected to show significant growth, supported by strong national immunization guidelines established by the Public Health Agency of Canada (PHAC). The country benefits from a dense network of hospitals, pharmacies, and dedicated travel clinics, ensuring broad access to pre-travel vaccination services. Canada’s proactive approach to travel-related disease prevention, combined with high outbound travel rates and strong public health infrastructure, continues to drive vaccine uptake across the country.
   

Germany is poised to achieve significant growth in the Europe travel vaccines market.
 

• Germany is emerging as a key growth market within Europe due to increasing outbound travel, advanced cold-chain logistics, and integration of digital health services.
   
• Recognized among the top outbound tourist nations, Germany benefits from a well-regulated healthcare system, with widespread access to vaccines via hospitals, travel clinics, and pharmacies.
   
• Government-backed preventive healthcare policies and the presence of global vaccine manufacturers contribute to market growth.
   
• With the post-pandemic rebound of international travel and growing adherence to global travel health guidelines, Germany is expected to experience accelerated growth in the regional market.
   

Asia Pacific is poised to grow at a significant growth rate in the global travel vaccines market over the next few years.
 

• China is projected to see strong growth due to the resurgence in outbound tourism, with 130 million travelers in 2024, expected to reach 200 million by 2028, as per the China Trading Desk.
   
• Government efforts, including visa-free entry policies, expanded international routes to 70+ countries, and increased public awareness, are propelling travel vaccine demand, particularly for Hepatitis A, yellow fever, typhoid, and rabies.
• Strengthening cold-chain infrastructure and public-private partnerships will further accelerate market momentum.
   
• Rising middle-class income, affordable air travel, and frequent business or educational travel are encouraging uptake of vaccines like Japanese encephalitis and typhoid.
   
• Further, government immunization, especially in collaboration with institutions like Serum Institute of India and Bharat Biotech, bolster regional supply. For instance, in December 2024, Valneva signed a partnership with Serum Institute to deliver a single-shot chikungunya vaccine across Asia, broadening access in low- and middle-income countries (LMICs).
   

Brazil is projected to witness significant growth in Latin America travel vaccines market in coming years.
 

• Brazil is emerging as a regional leader, driven by increased outbound travel, proactive immunization efforts, and strategic alliances between public health bodies and private providers.
   
• Government-supported programs and Brazil’s role as a hub for healthcare innovation contribute to increasing accessibility of vaccines against diseases such as yellow fever and Hepatitis A.
   
• Partnerships with regional health agencies have enhanced cold-chain logistics and outreach, thereby positioning Brazil as a key contributor to regional growth
   

Saudi Arabia is anticipated to grow in the Middle East and Africa travel vaccines market.
 

• Saudi Arabia’s travel vaccines market is witnessing robust expansion, led by rising international pilgrimages, increasing outbound travel, and public health modernization efforts under Vision 2030. In February 2025, Saudi authorities mandated vaccination certificates for meningitis for visitors, boosting vaccine demand.
   
• Expanded vaccination campaigns and digital platforms are strengthening public acceptance and compliance.
   
• Local manufacturing initiatives and partnerships with multinational pharmaceutical companies are improving vaccine availability and supply resilience.
   
• Growth in South Africa is supported by regional travel policies and increasing healthcare awareness. Cross-border travel within Sub-Saharan Africa and the adoption of WHO-aligned immunization strategies are driving demand for routine and travel-specific vaccines.
• Government and NGO-led outreach programs are also fostering wider immunization coverage in underserved areas.
   

Travel Vaccines Market Share

The leading companies such as GlaxoSmithKline plc (GSK), Sanofi, Pfizer, CSL and Merck hold 72% of the market share. These companies are shaping the competitive landscape through robust R&D capabilities, strategic partnership and expanding distribution network. The companies are continuously striving to expand their capabilities to offer comprehensive vaccines such as typhoid vaccines, Hepatitis A and Hepatitis B vaccines, yellow fever and Japana encephalitis vaccines that are crucial for domestic as well as outbound travelers to high-risk regions.
 

The emerging players such as Valneva, Bavarian Nordic and Serum Institute of India are gaining traction through niche innovation such as vaccines for chikungunya and Japanese encephalitis. Further, Serum Institute of India is expanding vaccines reach by offering cost-effective solutions along with strategic distribution partnerships to Asian market.
 

Travel Vaccines Market Companies

Few of the prominent players operating in the travel vaccines industry include:

• Bavarian Nordic
• Bharat Biotech
• CSL
• Dynavax Technologies
• Emergent BioSolutions
• GlaxoSmithKline plc (GSK)
• Meiji Group
• Merck
• Pfizer
• Sanofi
• Serum Institute of India
• Valneva SE
   
• GlaxoSmithKline plc (GSK)

GSK offers a robust portfolio of travel vaccines including Havrix (Hepatitis A) and Typherix (typhoid). Its innovation in combination vaccines and strategic partnerships with governments and travel clinics, combined with its extensive distribution network enhance its global reach and market position.
 

• Sanofi

Sanofi leadership is indicated from its expertise in travel-related diseases, offering vaccines for rabies, typhoid and yellow fever. The company leverages advanced R&D capabilities, manufacturing, and advanced cold-chain distribution service for medicines and vaccines, ensuring its reliability and global accessibility to its vaccine portfolio. Additionally, its global presence and focus on underserved regions enhances its influence in the travel health sector.
 

• Merck

Merck offer comprehensive vaccine, including DPT, MMR, and hepatitis vaccines. Its well-stated regulatory approvals, investment in vaccine technology, and public-private collaborations help it sustain high demand among travelers and global health programs.
 

• Pfizer

Pfizer is well known for its pioneering vaccine technologies and extensive distribution capabilities. Its travel vaccines benefit from cutting-edge research and high efficacy standards. Pfizer’s stands for rapid innovation, particularly post-COVID, and its strong regulatory compliance make it a preferred choice for travelers and healthcare providers worldwide.
 

Travel Vaccines Industry News:

• In March 2025, Bavarian Nordic A/S introduced a first virus like particle single-dose vaccine to 'Vimkunya', in U.S. Vimkunya was approved by the U.S. FDA, for individuals aged 12 and older. This initiative aims to proactively safeguard travelers against chikungunya virus and its potential long-term health effects.
   
• In February 2025, Valneva received the Medicines and Healthcare products Regulatory Agency (MHRA) grant for marketing its first chikungunya vaccine IXCHIQ in U.K. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus in individuals 18 years of age and older. This approval strengthened the global response to emerging infectious threats highlighting the emphasis on preventive healthcare measures.
   
• In February 2024, Takeda signed a strategic manufacturing partnership agreement with Biological E to accelerate the access to QDENGA, a dengue tetravalent vaccine. This collaboration aims to accelerate vaccine availability amid rising dengue cases driven by urbanization, increased travel, and climate change. The partnership represented a fundamental step towards dengue prevention, combining innovation and scale to address a growing public health challenge.
   

The travel vaccines market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Mono vaccines
• Combination vaccines

Market, By Disease Type

• Hepatitis A
• Meningococcal diseases
• Influenza
• Diphtheria, pertussis, tetanus (DPT)
• Rabies
• Yellow fever
• Typhoid
• Measles, mumps, and rubella (MMR)
• Hepatitis B
• Other disease types

Market, By Application

• Outbound travel
• Domestic travel

Market, By Age Group

• Pediatric
• Adult

Market, By End Use

• Hospitals
  • Public
  • Private
• Specialty clinics
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE